| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | NPPB, Natriuretic Peptide Precursor B, BNP, B-type Natriuretic Peptide. |
| Cellular Localization | |
| Expression System | |
| Form | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | |
| Product Type | |
| Protein Length | |
| Purity | |
| Solubility | It is recommended to reconstitute the lyophilized B-type Natriuretic Peptide in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions. |
| Source | Escherichia Coli. |
| Species | |
| Storage | |
| Target |
Recombinant Human B-type Natriuretic Protein is supplied as a recombinant protein for in vitro research use.
Background
Natriuretic Peptide Precursor B acts as a cardiac hormone with a variety of biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. It is thought to play a key role in cardiovascular homeostasis. Helps restore the body's salt and water balance. Improves heart function.
B-Type Natriuretic Peptide Human Recombinant: Expanding the Horizons of Cardiovascular Medicine Abstract: B-Type Natriuretic Peptide (BNP) human recombinant is a significant biomarker and therapeutic agent in the field of cardiovascular medicine. This research paper aims to provide an in-depth analysis of BNP, including its physiological role, diagnostic utility, and therapeutic potential. Furthermore, innovative methodologies for the production and application of BNP human recombinant are proposed, emphasizing its promising prospects in cardiovascular disease management. Introduction: Cardiovascular diseases (CVDs) pose a global health burden, necessitating novel diagnostic and therapeutic strategies. BNP, a cardiac hormone, has emerged as a valuable tool in the assessment and management of CVDs. This paper delves into the distinctive characteristics of BNP and explores its diagnostic and therapeutic implications, shedding light on its potential as a game-changer in cardiovascular medicine. Physiological Role and Mechanisms: BNP is primarily secreted by the ventricular myocardium in response to increased cardiac wall stress. It exerts its effects through binding to the natriuretic peptide receptor, stimulating cyclic guanosine monophosphate (cGMP) production and promoting vasodilation, natriuresis, and diuresis. Additionally, BNP counteracts the renin-angiotensin-aldosterone system, antagonizing the deleterious effects of cardiac remodeling and fibrosis. Diagnostic Utility: BNP levels serve as a reliable biomarker for the diagnosis, risk stratification, and monitoring of various cardiovascular conditions, including heart failure, myocardial infarction, and pulmonary hypertension. Measurements of BNP and its inactive fragment, N-terminal pro-BNP (NT-proBNP), aid in the accurate assessment of cardiac function, guiding therapeutic decisions and predicting clinical outcomes. Production and Application of BNP Human Recombinant: Efficient production methodologies and innovative applications of BNP human recombinant play a pivotal role in advancing cardiovascular medicine. Recombinant protein expression systems, such as bacterial expression systems and mammalian cell culture, have been employed to produce functional BNP. Novel strategies, including targeted delivery systems and BNP-based therapies, hold promise for enhancing the therapeutic efficacy and reducing the adverse effects associated with traditional treatment approaches. Therapeutic Potential: BNP human recombinant demonstrates significant therapeutic potential in the management of cardiovascular diseases. Synthetic BNP analogs, including neprilysin inhibitors, offer novel approaches to enhance endogenous BNP signaling and improve cardiac function. Furthermore, BNP-based therapies, such as gene therapy and BNP receptor agonists, hold promise in promoting myocardial regeneration, attenuating cardiac remodeling, and improving clinical outcomes in heart failure patients. Conclusion: BNP human recombinant emerges as a promising avenue in cardiovascular medicine, contributing to the diagnosis, risk stratification, and therapeutic interventions for various cardiovascular conditions. Optimization of production methodologies and exploration of novel therapeutic strategies will further enhance the clinical applications of BNP. Leveraging the potential of BNP as a diagnostic biomarker and therapeutic agent may revolutionize the management of cardiovascular diseases, improving patient outcomes and quality of life.
Product format
Provided as a recombinant protein suitable for in vitro workflows such as binding studies, screening, and assay development. Refer to the specifications table for expression format and molecular properties.
What is the purity of Recombinant Human B-type Natriuretic Protein (Human)?
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE. BioHippo includes a Certificate of Analysis (CoA) confirming purity per lot with every order.
What buffer / formulation is this protein supplied in?
How should Recombinant Human B-type Natriuretic Protein (Human) be stored?
What expression system was used to produce this protein?
Is this protein approved for clinical or in vitro diagnostic use?
Can I request a custom size, tag variant, or formulation?
Can’t Find What You’re Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
